BPC-157 is prohibited by WADA and should not be used by athletes subject to drug testing
8 BPC-157 + TB-500 Case Series (PubMed)Small, low-quality case series of combined BPC-157 and TB-500 for joint injury at higher, intra-articular doses
Injections offer superior bioavailability, especially for *Vitamin B12*, which can be poorly absorbed orally in some individuals
In most cases, treatment for B12 deficiency is effective, and a person will not continue to have symptoms
Reactions that warrant attention include persistent swelling or redness lasting more than 24 hours, significant pain beyond the initial injection moment, the development of hard nodules that do not resolve within a day or two, fever or systemic symptoms following injection, or any sign of infection at the injection site including warmth, pus, or spreading redness